The National Agency for Food and Drug Administration and Control has issued a nationwide alert and ordered the immediate recall of several pharmaceutical products manufactured by Europharm Laboratories, following findings of large-scale regulatory violations and substandard drug production.
NAFDAC, in a statement posted on its official X handle on Friday, said it had commenced enforcement actions against Europharm Laboratories and its affiliate, Eurolink Nigeria Ltd, located at Plot PL 7354, Anglo Jos New Industrial Area, Plateau State.
The agency explained that the action followed credible intelligence, routine regulatory surveillance and laboratory investigations, which uncovered that the company was producing, selling and distributing several medicines without valid marketing authorisation.
According to NAFDAC, a raid on the facility led to the discovery of multiple pharmaceutical products that violated existing regulations, while laboratory analysis of seized samples revealed serious quality defects capable of endangering public health.
“The laboratory tests showed dangerously low levels of Active Pharmaceutical Ingredients in some of the products,” the agency disclosed.
NAFDAC specifically revealed that Linmoxyn Amoxicillin suspension failed quality analysis, with API levels as low as 13.9 per cent and 18.4 per cent, far below the acceptable standard. Similarly, Linmoxyn Amoxicillin 500mg capsules were found to contain only 48.3 per cent API.
The agency warned that medicines with insufficient API content could lead to treatment failure, worsen illnesses, encourage antimicrobial resistance and expose patients to severe health risks.
Other products identified during the investigation include Linocloxin Ampicillin and Cloxacillin powder for oral suspension, Linromycine Erythromycin powder for suspension, Linocillin Ampicillin powder, Linmoxyn Amoxicillin suspension, Eurogyl Metronidazole suspension and tablets, Naflin cough expectorant, Natacid Magnesium Trisilicate suspension, Navit B Syrup, Fountain B12 blood tonic, Vitamin C syrup, Euramol Paracetamol tablets, Euramox Mebendazole tablets, Linotrim Cotrimoxazole suspension and Linoquine Chloroquine Phosphate syrup.
NAFDAC added that several of the affected products bore NAFDAC registration numbers, raising further concerns about regulatory abuse and consumer deception.
The agency said it had directed all zonal directors and state coordinators across the country to intensify surveillance, remove the affected products from circulation and ensure compliance within their jurisdictions.
NAFDAC urged distributors, retailers, healthcare professionals and caregivers to remain vigilant within the drug supply chain to prevent the continued distribution and use of unsafe medicines.
Members of the public and medical practitioners were also advised to promptly report any suspected substandard or falsified medicines to the nearest NAFDAC office.
The agency reaffirmed its commitment to safeguarding public health and warned that it would not hesitate to sanction companies found endangering lives through the production or distribution of substandard drugs.
'
'Do you want to share a story with us? Do you want to advertise with us? Do you need publicity for a product, service, or event? Contact us on WhatsApp +2348183319097 Email: platformtimes@gmail.com
We are committed to impactful investigative journalism for human interest and social justice. Your donation will help us tell more stories. Kindly donate any amount HERE
